Four Ketamine Clinics Explain the Dose Better Than the Goodbye

Picture the last troche in its foil pouch. A troche is a medicated lozenge designed to dissolve in the mouth, and for patients using prescribed ketamine at home, that small square can mark several endings at once: the final dose in a package, the expiration of a subscription, or a clinician's decision that treatment should stop.

The clinic was easy to enter. There was an eligibility form, a video consultation, shipping information and a sequence of reminders. The exit is harder to see. Does somebody schedule a final appointment?

Does the clinic send records to a psychiatrist or primary care clinician? If the patient's symptoms worsen after access ends, is there a person to call, or only a page explaining that the platform is not an emergency service?

I compared the public-facing documentation of Mindbloom, Joyous, Better U and Innerwell, focusing on four things: discharge, changes in dosing near the end of care, referral to another provider and crisis response. This is a review of what a prospective patient can verify before handing over money, not an assessment of private instructions inside member portals or individualized clinical decisions. It is also not medical advice.

The pattern is plain. These companies are much better at describing the treatment journey while the commercial relationship remains active than the handoff after it ends.

Mindbloom: the program has an ending, but discharge stays indistinct

Mindbloom presents care as a structured program rather than an indefinite bottle refill. Its public materials describe clinician involvement, preparation, guided sessions and integration, the work of processing an experience afterward. That structure gives the treatment a visible arc. It also makes the missing final scene easier to notice.

The company publishes eligibility and safety information, explains that ketamine is not appropriate for everyone, and directs people experiencing emergencies toward emergency services rather than the platform. Its materials also describe opportunities to continue with further programming. What is harder to locate publicly is a standard discharge document stating what every client receives when the program ends: a closing clinical review, a medication plan, a copy of records, referral criteria and a defined period for follow-up questions.

That distinction matters. An integration session near the end of a paid program may be useful, but integration is not automatically discharge planning. One addresses the meaning and use of treatment experiences. The other assigns responsibility after the clinic is no longer delivering them.

Mindbloom's bounded format at least tells a client to expect an endpoint. Yet the last troche still sits beside an unresolved administrative question: whether the next step is discharge, another program or a search for outside care conducted largely by the patient.

Joyous: cancellation is clear, continuity is not

Joyous sells a lower-dose model through a recurring subscription, with ongoing check-ins and dose adjustments described as part of the service. The subscription mechanism changes what an ending looks like. There may be no ceremonial final session. Treatment can instead conclude when the member cancels, becomes ineligible, stops responding or receives a clinical instruction to stop.

Public Joyous materials discuss cancellation, treatment duration and communication with its care team. They do not present dose changes as something a member should manage alone. Still, a billing exit is not a clinical discharge protocol, and the public documents do not make a universal handoff package easy to identify.

A prospective member cannot readily see whether cancellation automatically triggers a final clinician review, how long messaging access continues, whether records arrive without a separate request, or when Joyous will arrange a referral rather than tell the member to contact another clinician. Individual members may receive more support than the website promises. That is precisely the problem with relying on discretion: continuity becomes something a patient discovers at the point of departure.

The subscription works well for the provider while treatment continues. Revenue recurs, check-ins remain inside the platform and medication management belongs to the same closed loop. Once payment stops, every task that crosses the platform boundary becomes more expensive and less commercially useful.

Better

U: a finite package with an uncertain handoff

Better U markets at-home ketamine through treatment packages that combine medical screening, medication and support around the sessions. The finite package makes the final supplied dose visible from the beginning. A customer can count what remains.

Its public materials emphasize preparation, coaching or integration, safety requirements and access to a care team during treatment. They also distinguish the service from emergency care. Yet the same public surface does not offer a comparably detailed, standard discharge pathway for the moment after a package is completed or a patient is no longer eligible.

The distinction between additional treatment and continuity appears here again. Selling or discussing another package answers whether the platform can keep treating someone. It does not answer what happens when the person should not continue, cannot afford to continue or wants their next clinician to take over. A genuine handoff requires records, an accountable sender and a receiving service willing to accept the patient.

A link to a directory does not complete that transfer.

With the last foil pouch still unopened, the customer can see the product ending more clearly than the care relationship.

Innerwell: support during treatment, fewer public promises after it

Innerwell also frames at-home ketamine as a planned course, pairing prescribing and monitoring with preparation or integration support. Its public documentation describes screening, clinician contact and the treatment period in considerably more detail than the post-treatment period.

As with the other providers, crisis language draws a firm boundary. Online ketamine care is not positioned as an emergency service, and people in immediate danger are directed toward public crisis systems or emergency departments. That boundary is clinically understandable. It is also where the private wellness market reveals its dependence on public infrastructure: the company can sell scheduled care while 988, hospitals and local services absorb emergencies that do not fit the product.

Innerwell's public pages do not make a universal external referral or post-discharge monitoring period obvious. Continued treatment may be available for some patients, but continuation inside the same company is different from continuity across providers. One extends a customer relationship. The other preserves care when that relationship ends.

The business model stops at the platform boundary

None of this proves that these clinics abandon patients. Public websites are incomplete, clinicians can make individualized plans, and private portals may contain instructions that marketing pages omit. The narrower finding is still consequential: before enrollment, a patient often cannot compare discharge quality with the same confidence that they can compare convenience, program design or what arrives by mail.

The incentives explain the asymmetry. Telehealth ketamine companies get paid for assessment, medication management, treatment packages and subscriptions. Preparation and integration can be bundled into those products. A warm handoff, meaning direct coordination with a receiving clinician rather than a generic recommendation to seek care, consumes staff time after future revenue has become uncertain.

Records must be prepared. Releases must be signed. Outside offices must be contacted, sometimes repeatedly. A clinician may need to explain why treatment ended and what remains unresolved.

That labor is ordinary continuity of care, but it does not photograph well, fit neatly into an onboarding funnel or encourage renewal.

Crisis disclaimers solve a different institutional problem. They tell patients where the clinic's responsibility is limited and route acute danger toward services designed to handle it. They do not tell a stable but struggling patient who will monitor symptoms next month, help locate an in-network psychiatrist or respond if the end of treatment goes badly without becoming an immediate emergency.

A credible public discharge standard would be unglamorous. It would state when a closing review occurs, who decides whether dosing changes are needed, how unused medication should be handled under the provider's instructions, how records are obtained, what referral assistance means and how long clinical messaging remains open. It would separate voluntary cancellation from clinical discharge and loss of eligibility, because those exits create different risks.

No company needs to promise endless access. It should have to describe the edge of the service before a patient reaches it.

The last troche is not just a dose. It is the point where a polished treatment journey becomes a transfer of labor, and the person who paid for care may be left carrying the records, the phone calls and the search for whoever comes next.

Questions people ask

Does ketamine treatment always need to be tapered?

There is no single public tapering rule across these providers, and dosing decisions depend on the prescription and the patient. The relevant consumer question is whether the clinic promises a clinician-led ending rather than leaving medication changes to a cancellation screen. Patients should follow their prescriber's instructions, not a general article or another member's routine.

Will an online ketamine clinic refer me to another provider?

The reviewed public materials do not make a completed external referral a universal promise. Some clinics may recommend follow-up or coordinate care case by case, but a recommendation is weaker than a warm handoff in which records are sent and a receiving clinician is identified.

What happens if someone is in crisis after treatment ends?

Where crisis instructions appear, the providers direct emergencies toward 911, 988 or an emergency department rather than their routine telehealth channels. That may be appropriate for immediate danger, but it does not replace follow-up care for worsening symptoms that have not crossed an emergency threshold.

What should be clear before someone pays for a program?

The public documents should identify the final clinical contact, access to records, rules for unused medication, referral support and the duration of messaging after treatment ends. If those terms are unavailable before enrollment, the patient is being asked to buy a care journey without seeing its exit.